Abstract
Pembrolizumab, an anti-PD 1 antibody, has been approved for the treatment of metastatic melanoma [1, 2], non-small cell lung carcinoma [3, 4], and head and neck cancers [5]; and is being investigated in other cancers. We describe a case of Pembrolizumab induced severe bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.